Form 4: OnKure Therapeutics Director Reports Changes in Beneficial Ownership Following Merger

Director R Michael Carruthers reports changes in beneficial ownership of OnKure Therapeutics stock following the merger with Reneo Pharmaceuticals.

Summary

• R Michael Carruthers, a director of OnKure Therapeutics, filed a Form 4 detailing changes in beneficial ownership of the company's stock.
• The filing is related to the merger between Reneo Pharmaceuticals and OnKure, which was completed on October 4, 2024.
• As a result of the merger, OnKure, Inc. became a wholly-owned subsidiary of Reneo, and the combined company was renamed 'OnKure Therapeutics, Inc.'
• Shares of OnKure common stock and Series C preferred stock were converted into Reneo Class A Common Stock based on a designated exchange ratio.
• Carruthers acquired 874 shares of Class A Common Stock and 4,065 restricted stock units (RSUs).
• Carruthers also holds options to purchase 1,760 shares at $21.20, 1,324 shares at $13.99 and 15,300 shares at $18.20.
• The RSUs represent a contingent right to receive one share of Class A Common Stock upon meeting certain service and liquidity requirements.
• The stock options held by Carruthers were assumed by Reneo and converted into options to acquire Reneo Class A common stock, with adjustments to the number of shares and exercise price based on the exchange ratio.
• Some of the options are fully vested, while others vest over time, contingent on continued service.
• The filing was signed by Rogan Nunn, by power of attorney, on October 8, 2024.

Sentiment

Score: 7

Explanation: The document is a routine regulatory filing related to a merger. While the merger itself could be viewed positively, the filing is simply a factual report of changes in ownership. The sentiment is neutral to slightly positive.

Positives

• The merger's completion provides clarity on the company's structure and future direction.
• Carruthers' continued holdings, including stock and options, suggest confidence in the combined company's prospects.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules of the RSUs and stock options.

Industry Context

This filing reflects the completion of a merger in the pharmaceutical industry, where such transactions are common for companies seeking to expand their pipelines, technologies, or market presence. Mergers often lead to changes in ownership and management structures, as reflected in this Form 4 filing.

Comparison to Industry Standards

• Form 4 filings are standard practice following mergers and acquisitions in publicly traded companies, ensuring transparency regarding changes in insider ownership.
• The conversion of stock options and RSUs based on an exchange ratio is a typical mechanism in mergers to preserve the economic value of existing equity awards for employees and directors.
• The vesting schedules of the RSUs and stock options are consistent with standard equity compensation practices in the biotech industry, designed to incentivize long-term service and performance.

Stakeholder Impact

• Shareholders of both Reneo and OnKure are impacted by the merger, as their shares have been converted into shares of the combined company.
• Employees of OnKure are impacted as the company becomes a subsidiary of Reneo, potentially affecting their roles and responsibilities.
• The merger may impact the company's strategic direction, potentially affecting customers and partners.

Key Dates